{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T17:01:00Z","timestamp":1789837260942,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2001,3,1]],"date-time":"2001-03-01T00:00:00Z","timestamp":983404800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2001,3]]},"DOI":"10.1007\/s11906-001-0105-8","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T22:18:14Z","timestamp":1180131494000},"page":"S31-S33","source":"Crossref","is-referenced-by-count":6,"title":["Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease"],"prefix":"10.1007","volume":"3","author":[{"given":"Eiji","family":"Kubota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael G.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Hubner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne C.","family":"Balding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin I.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"105_CR1","doi-asserted-by":"crossref","first-page":"24S","DOI":"10.1016\/S0002-9343(89)80481-4","volume":"87","author":"CI Johnston","year":"1989","unstructured":"Johnston CI, Hodsman PG, Kohzuki M, et al.: Interaction between atrial natriuretic peptide and the renin angiotensin aldosterone system. Endogenous antagonists. Am J Med 1989, 87:24S-28S.","journal-title":"Am J Med"},{"key":"105_CR2","first-page":"118","volume":"45","author":"BP Roques","year":"1993","unstructured":"Roques BP, Noble F, Dauge V, et al.: Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993, 45:118\u2013146.","journal-title":"Pharmacol Rev"},{"key":"105_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","volume":"339","author":"ER Levin","year":"1998","unstructured":"Levin ER, Gardner DG, Samson WK: Mechanisms of disease \u2014 natriuretic peptides. N Engl J Med 1998, 339:321\u2013328.","journal-title":"N Engl J Med"},{"key":"105_CR4","first-page":"S37","volume":"17","author":"JC Burnett Jr","year":"1999","unstructured":"Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17:S37-S43.","journal-title":"J Hypertens"},{"key":"105_CR5","doi-asserted-by":"crossref","first-page":"139S","DOI":"10.1016\/S0895-7061(99)00205-8","volume":"12","author":"M Weber","year":"1999","unstructured":"Weber M: Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999, 12:139S-147S.","journal-title":"Am J Hypertens"},{"key":"105_CR6","first-page":"191","volume-title":"Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery","author":"LM Burrell","year":"2000","unstructured":"Burrell LM, Johnston CI: Clinical trials of ACE inhibitors: pathogenetic insights and therapeutic advances. In Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery. Edited by Husain A, Graham RM. Australia: Harwood Academic Publishers; 2000:191\u2013200."},{"key":"105_CR7","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0895-7061(00)01185-7","volume":"13","author":"LM Burrell","year":"2000","unstructured":"Burrell LM, Droogh J, In\u2018t Veld OM, et al.: Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 2000, 13:1110\u20131116.","journal-title":"Am J Hypertens"},{"key":"105_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004872-200018060-00013","volume":"18","author":"NK Farina","year":"2000","unstructured":"Farina NK, Johnston CI, Burrell LM: Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens 2000, 18:1\u20137.","journal-title":"J Hypertens"},{"key":"105_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1080\/140174398428063","volume":"32","author":"CI Johnston","year":"1998","unstructured":"Johnston CI, Naitoh M, Risvanis J, et al.: New hormonal blockade strategies in cardiovascular disease. Scand Cardiovasc J 1998, 32:61\u201366.","journal-title":"Scand Cardiovasc J"},{"key":"105_CR10","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1161\/01.HYP.36.6.1105","volume":"36","author":"LM Burrell","year":"2000","unstructured":"Burrell LM, Farina NK, Balding LC, et al.: Beneficial renal and cardiac effects of vasopeptidase inhibition with S21402 in heart failure. Hypertension 2000, 36:1105\u20131111.","journal-title":"Hypertension"},{"key":"105_CR11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1097\/00005344-199912000-00003","volume":"34","author":"NC Trippodo","year":"1999","unstructured":"Trippodo NC, Fox M, Monticello TM, et al.: Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999, 34:782\u2013790.","journal-title":"J Cardiovasc Pharmacol"},{"key":"105_CR12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","volume":"356","author":"JL Rouleau","year":"2000","unstructured":"Rouleau JL, Pfeffer MA, Stewart DJ, et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000, 356:615\u2013620.","journal-title":"Lancet"},{"key":"105_CR13","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1001\/jama.283.24.3177","volume":"283","author":"ME Cooper","year":"2000","unstructured":"Cooper ME, Johnston CI: Optimizing treatment of hypertension in patients with diabetes. JAMA 2000, 283:3177\u20133179.","journal-title":"JAMA"},{"key":"105_CR14","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1161\/01.HYP.32.4.778","volume":"32","author":"T Tikkanen","year":"1998","unstructured":"Tikkanen T, Tikkanen I, Rockell MD, et al.: Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998, 32:778\u2013785.","journal-title":"Hypertension"},{"key":"105_CR15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1046\/j.1523-1755.2001.060002715.x","volume":"60","author":"Z Cao","year":"2001","unstructured":"Cao Z, Burrell LM, Tikkanen I, et al.: Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001, 60:715\u2013721.","journal-title":"Kidney Int"},{"key":"105_CR16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005344-199807000-00014","volume":"32","author":"DS Cohen","year":"1998","unstructured":"Cohen DS, Mathis JE, Dotson RA, et al.: Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 1998, 32:87\u201395.","journal-title":"J Cardiovasc Pharmacol"},{"key":"105_CR17","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.HYP.37.4.1047","volume":"37","author":"VJ Dzau","year":"2001","unstructured":"Dzau VJ: Tissue angiotensin and pathobiology of vascular disease \u2014 a unifying hypothesis. Hypertension 2001, 37:1047\u20131052.","journal-title":"Hypertension"},{"key":"105_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00005344-200104000-00002","volume":"37","author":"MJ Dumoulin","year":"2001","unstructured":"Dumoulin MJ, Adam A, Rouleau JL, et al.: Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed. J Cardiovasc Pharmacol 2001, 37:359\u2013366.","journal-title":"J Cardiovasc Pharmacol"},{"key":"105_CR19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/01.HYP.37.1.28","volume":"37","author":"LV d\u2018Uscio","year":"2001","unstructured":"d\u2018Uscio LV, Quaschning T, Burnett JC, et al.: Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. Hypertension 2001, 37:28\u201333.","journal-title":"Hypertension"},{"key":"105_CR20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0021-9150(00)00565-7","volume":"155","author":"JF Arnal","year":"2001","unstructured":"Arnal JF, Castano C, Maupas E, et al.: Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein Edeficient mice. Atherosclerosis 2001, 155:291\u2013295.","journal-title":"Atherosclerosis"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0105-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-001-0105-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-001-0105-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:16:01Z","timestamp":1559434561000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-001-0105-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":20,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1007\/s11906-001-0105-8","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}